Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
Pfizer's Weight Loss Injection GLP-1 Ecnoglutide Injection Approved in CN
Recommend 4 Positive 4 Negative 6 |
||||
|
||||
|
Pfizer China announced that the National Medical Products Administration (NMPA) has officially approved the new-generation cAMP-biased GLP-1 receptor agonist, ecnoglutide injection (Xianweiying), for long-term weight management in overweight and obese adults, in conjunction with dietary control and increased physical activity. At the end of last month, Pfizer (PFE.US) acquired the exclusive distribution rights for the therapy in China from Sciwind Biosciences for US$495 million. Pfizer has not yet announced the pricing or launch date for Xianweiying. The approval by the NMPA comes as the patent for Novo Nordisk A/S (NVO.US)'s Wegovy is set to expire later this month, potentially opening the market for more affordable generic drugs. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
